ClinicalTrials.gg

Program

zelicapavir

Also written as “EDP-938”, “zelicapavir (therapeutic dose)” and “zelicapavir (supratherapeutic dose)”.

Its studies are mostly in Respiratory Syncytial Virus Infections · Pulmonary Disease, Chronic Obstructive, led by Enanta Pharmaceuticals.

Furthest: phase 3, since Oct 26, 202614 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Enanta Pharmaceuticals142 open or runningphase 3since Oct 26, 2026Dec 20, 2017Dec 2026phase 2 · NCT07482657

Also a collaborator on its studies: ppd-development-lp and hvivo-services-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2017First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT03384823 · 90 enrolled · United States
  2. Sep 28, 2018Phase 2 study in Respiratory Syncytial Virus InfectionsNCT03691623 · 179 enrolled · United Kingdom
  3. Nov 8, 20182 phase 1 studies in Respiratory Syncytial Virus InfectionsNCT03750383, NCT03755778
  4. Dec 3, 2019Phase 2 study in Respiratory Syncytial VirusNCT04196101 · 82 enrolled · United States, Argentina, Bulgaria and more
  5. Jul 30, 2020Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04498741 · 89 enrolled · United States
  6. Nov 11, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsNCT04633187 · 9 enrolled · United States, Argentina, Belgium and more
  7. Mar 23, 2021Phase 2 study in Respiratory Syncytial Virus (RSV)NCT04816721 · 99 enrolled · United States, Argentina, Australia and more
  8. Apr 29, 2021Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04871724 · 24 enrolled · United States
  9. Jun 9, 2021Phase 1 study in Respiratory Syncytial Virus (RSV)NCT04927793 · 8 enrolled · United States
  10. Oct 3, 2022Phase 2 study in Respiratory Syncytial Virus InfectionsNCT05568706 · 187 enrolled · United States, Argentina, Bulgaria and more
  11. Aug 27, 2024Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06601192 · 72 enrolled · United States
  12. Mar 16, 2026Phase 2 study in Respiratory Syncytial Virus InfectionsNCT07482657 · 150 planned · Thailand
  13. Oct 26, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07908381 · 860 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT07482657
  2. Jul 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07908381

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908381Pulmonary Disease, Chronic Obstructive · United States3RecruitingJul 2029860
NCT07482657Respiratory Syncytial Virus Infections · Thailand2RecruitingDec 2026150
NCT06601192Respiratory Syncytial Virus Infections · United States1CompletedFeb 2, 202572
NCT05568706Respiratory Syncytial Virus Infections · United States, Argentina, Bulgaria and more2CompletedJun 23, 2025187
NCT04927793Respiratory Syncytial Virus (RSV) · United States1CompletedJul 4, 20218
NCT04871724Respiratory Syncytial Virus Infections · United States1CompletedMar 30, 202124
NCT04816721Respiratory Syncytial Virus (RSV) · United States, Argentina, Australia and more2CompletedAug 19, 202499
NCT04633187Respiratory Syncytial Virus Infections · United States, Argentina, Belgium and more2TerminatedMay 31, 20239
NCT04498741Respiratory Syncytial Virus Infections · United States1CompletedMay 27, 202189
NCT04196101Respiratory Syncytial Virus · United States, Argentina, Bulgaria and more2CompletedJan 4, 202282
NCT03755778Respiratory Syncytial Virus Infections · United States1CompletedJan 21, 201972
NCT03750383Respiratory Syncytial Virus Infections · United States1CompletedNov 17, 201848
NCT03691623Respiratory Syncytial Virus Infections · United Kingdom2CompletedSep 30, 2019179
NCT03384823Respiratory Syncytial Virus Infections · United States1CompletedJul 3, 201890

How it is read

Names in the registry

  • “EDP-938”, 16 entries
  • “zelicapavir”, 2 entries
  • “zelicapavir (therapeutic dose)”, 1 entry
  • “zelicapavir (supratherapeutic dose)”, 1 entry
  • “EDP-938 Dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.